Expert opinion on biological therapyHumansAntibodiesBispecificLymphomaB-Cell
Bispecific antibody combination regimens for B-cell non-Hodgkin's lymphomas.
Khushali Jhaveri, Aditi Saha, Luis Miguel Juarez-Salcedo, Julio C Chavez
Published: 202510.1080/14712598.2025.2597847
Abstract
INTRODUCTION: Bispecific antibodies (BsAbs) are a novel class of immunotherapy agents that engage endogenous T cells to target and eradicate malignant B cells by simultaneously binding CD3 and CD20. BsAbs such as epcoritamab, glofitamab, and mosunetu…
Preview only. Read the full abstract at the source